1	Induction of poxviral immunity by synthetic MVA-based dual-antigen COVID-19 vaccine
2	COH04S1
3	Flavia Chiuppesi*; John A. Zaia ¹ ; Sandra Ortega Francisco; Minh Ly; Felix Wussow and Don J.
4	Diamond*
5	Department of Hematology and HCT and Hematologic Malignancies Research Institute, ¹ Center
6	for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA,
7	91010.
8	*FC and DJD are co-corresponding authors
9	
10	Corresponding Authors: F. Chiuppesi, <u>fchiuppesi@coh.org</u> ; D.J. Diamond, <u>ddiamond@coh.org.</u>
11	
12	Running title: Induction of poxviral immunity by COH04S1
13	

14 Summary

15 The recent outbreak of monkeypox outside its endemic boundaries has attracted global 16 attention and prompted world leaders to reserve thousands of doses of the only approved third-17 generation smallpox/monkeypox vaccine Jynneos, which is based on the highly attenuated 18 modified vaccinia Ankara (MVA) vector. Given the potential urgency to vaccinate individuals at 19 risk in both endemic and non-endemic countries to curtail further spread of the outbreak, there 20 is a legitimate need for substantial doses of smallpox/monkeypox vaccines. We previously developed COH04S1, a multiantigen SARS-CoV-2 vaccine candidate built on a synthetic MVA 21 22 platform. COH04S1 was found to be safe and to induce SARS-CoV-2-specific immune 23 responses in healthy adults participating in a phase 1, blinded, randomized, placebo-controlled 24 clinical trial. Here we perform a retrospective analysis of vaccine-induced orthopoxvirus 25 immunity in a subgroup of volunteers enrolled in the phase 1 clinical trial that were vaccinated 26 with COH04S1 at different doses. At all dose levels, vaccination with COH04S1 resulted in 27 robust MVA-specific binding and neutralizing antibody responses, which were sustained over six 28 months post-vaccination. Similarly, both CD8+ and CD4+ T cells specific for MVA were induced 29 by COH04S1 vaccination and remained durable for at least six months. Given that both arms of 30 the immune response are thought to be involved in protection against orthopoxvirus infections, 31 our results indicate that COH04S1 or other sMVA-based vaccines may represent valuable 32 candidates for smallpox/monkeypox vaccination.

33 Introduction

34 The unforeseen 2022 Monkeypox outbreak outside of its endemic boundaries has worried 35 health officials and renewed interest in testing and stockpiling of a safe and effective smallpox vaccine¹. Smallpox (or variola major), a poxvirus with a case-fatality rate of up to 30%, was 36 37 declared eradicated in 1980 after a very successful global vaccination campaign². Monkeypox 38 belongs to the same orthopoxvirus genus as smallpox and exists in two clades. The Central 39 African clade has a high mortality rate of 10%, while infection with the West African clade results 40 in about 1% case-fatality rate³. Monkeypox is endemic in some Central African countries, where it causes more than 1,000 cases annually³⁻⁵. The recent worldwide outbreak with epicenter in 41 42 Europe caused by the less severe West African clade has resulted in more than 16,000 cases globally (as of July 25th, 2022) with five reported deaths. The recently reported cases in children 43 44 and healthcare workers has prompted the WHO to declare monkeypox outbreak a global health 45 emergency.

46 Replication-competent vaccinia virus strains of different origin were used around the world for the smallpox vaccination campaign, which ended in 1972⁶. In the US, vaccinia strain Dryvax 47 48 grown on calf skin formed the first-generation smallpox vaccine and was later substituted by 49 ACAM2000, which was plaque purified from Dryvax and produced using modern cell culture 50 technology. While ACAM2000 was highly immunogenic, it was associated with a high risk of 51 myocarditis/pericarditis (1 in 175 naïve adults), and this risk also extended to close contacts of vaccinated subjects, posing a threat, albeit low, for children, pregnant women, and 52 immunocompromised individuals⁶. For this reason, use of ACAM2000 has been licensed with a 53 54 medication guide and its use restricted to designated U.S. military personnel and laboratory researchers working with certain poxviruses. 55

56 Modified vaccinia Ankara (MVA) is a highly attenuated, replication-defective orthopoxvirus that 57 was derived from its parental strain chorioallantois vaccinia virus Ankara by over 500 passages

on chicken embryo fibroblasts⁷. MVA was developed as a third-generation smallpox vaccine and 58 has been safely administered at the end of the smallpox eradication campaign to more than 59 120,000 individuals, including children with immunodeficiencies and HIV infected individuals⁸. 60 61 Recently, Bavarian Nordic's proprietary MVA strain MVA-BN has been approved by the FDA as 62 a smallpox and monkeypox vaccine under the name of Jynneos based on a phase 3 noninferiority trial comparing one dose of ACAM2000 with two intramuscular doses of Jynneos⁹ as 63 64 well as nonhuman primate studies using a lethal monkeypox virus challenge¹⁰. Consequently, Jynneos has been added to the Strategic National Stockpile (SNS) as a safer alternative to 65 66 ACAM2000 that could be administered to the broader population. Due to the recent monkeypox 67 outbreak, Jynneos is now offered in some countries as a prophylactic vaccine in at-risk subjects 68 and for ring vaccinations in possible contacts of infected individuals. Given its robust safety and 69 immunogenicity profile, MVA has also been extensively used as a viral vector for delivery of heterologous antigens and tested as a vaccine against infectious diseases and cancer^{8,11-13}. 70

71 We developed a fully synthetic MVA (sMVA) platform based on the genome sequence published by Antione *et al.*¹⁴ for reconstituting virus that is virtually identical to wild-type MVA in 72 terms of replication properties, host cell tropism, and immunogenicity¹⁵. Using this platform, 73 74 which allows rapid generation of sMVA recombinants encoding multiple transgenes, we 75 developed COH04S1, a multiantigen sMVA-based COVID-19 vaccine encoding for Spike (S) 76 and Nucleocapsid (N) antigens. COH04S1 has been extensively tested in small and large 77 animal models, demonstrating robust immunogenicity and protective efficacy against SARS-CoV-2 and its variants through intramuscular and intranasal routes of vaccination¹⁵⁻¹⁷. 78 79 Additionally, COH04S1 has been tested in a phase I, randomized, placebo-controlled clinical 80 trial in healthy adults, showing a remarkable safety profile and resulting in the induction of robust and durable humoral and cellular responses to both vaccine antigens^{18,19}. Currently, 81

82 COH04S1 is being evaluated in two phase 2 clinical trials in healthy adults and 83 immunocompromised patients (NCT04639466, NCT04977024).

Given the recent approval of MVA as a vaccine to prevent smallpox and monkeypox, we evaluated whether COH04S1-vaccinated individuals, besides developing immunity to SARS-CoV-2¹⁸, also mounted orthopoxviral-specific immunity. We found that COH04S1 vaccinees developed robust orthopoxviral-specific humoral and cellular immune responses for up to sixmonths post vaccination, suggesting that COH04S1 could be a unique dual-agent vaccine candidate to simultaneously control the COVID-19 pandemic and the unforeseen global monkeypox outbreak.

92 Results

93 Study design to evaluate orthopoxviral immunity in COH04S1 vaccinees

94 We retrospectively evaluated orthopoxviral-specific humoral and cellular immune responses for 95 up to six months after vaccination with sMVA COVID-19 vaccine candidate COH04S1 in a 96 subgroup of 20 volunteers enrolled in a phase 1 clinical trial aimed at testing safety and immunogenicity of COH04S1 at different dose levels (DL) (NCT04639466)¹⁸. Subjects were 97 prime-boost vaccinated with low-dose (DL1, 1x10⁷ plague forming units [pfu]), medium-dose 98 99 (DL2, 1x10⁸ pfu), or high-dose (DL3, 2.5x10⁸ pfu) of vaccine. Of the 20 subjects vaccinated with 100 COH04S1, 15 (5 subjects/group) received two DL1, DL2, or DL3 vaccinations 28 days apart, 101 and 5 received two DL1 vaccinations 56 days apart with a placebo dose at day 28 102 (DL1/placebo/DL1). Four placebo-vaccinated subjects enrolled in the same trial were included 103 as controls. Subjects were not required to provide their smallpox vaccination status, and 104 poxvirus serostatus at enrollment was not evaluated. However, an exclusion criterion was any 105 poxvirus-vaccination in the six months before enrolling in the trial. Summary of study subjects, 106 vaccination schedule and age at enrollment is presented on Table S1.

107 Orthopoxviral-specific binding antibodies induced in COH04S1-vaccinated subjects

108 MVA-specific IgG binding antibodies in serum of COH04S1 vaccinated subjects were measured 109 against whole MVA virions by ELISA. Low binding (O.D.<0.4 nm) at low serum dilution (1:150) 110 was measured at baseline in most subjects (Figure S1). In contrast to all placebo control 111 volunteers, all subjects vaccinated with COH04S1 showed an increase in MVA-specific IgG 112 titers post-vaccination regardless of the dose vaccination regimen (Figure 1), demonstrating 113 potent vaccine-elicited orthopoxviral-specific humoral immunity. Elevated MVA-specific IgG 114 titers were measured following prime vaccination at all dose levels, although MVA IgG titers in 115 DL2 and DL3 subjects tended to be higher than those in DL1 subjects, indicating a dose 116 dependent response (Figure 1A-B). While DL1 cohorts had a seroconversion rate of 30-60%

117 following prime vaccination, DL2 and DL3 subjects showed 100% seroconversion after the first dose (Figure 1C). MVA-specific IgG titers further increased in all vaccine cohorts following the 118 119 second dose resulting in similar responses in DL1 and DL2/3 subjects and 100% 120 seroconversion in all vaccine cohorts. MVA-specific IgG titers slowly declined over five-months 121 post vaccination in all vaccine cohorts, but they remained at elevated levels over baseline in all 122 subjects independent of the dose immunization regimen, except for one subject in the DL1 123 cohort. Notably, two subjects in the DL1 and DL3 cohorts - one subject born in 1971 and one 124 subject born in 1986 - had high IgG endpoint titers of 4,050 and 1,350 before vaccination, 125 possibly indicating pre-existing orthopoxviral immunity (Figure S1). These two subjects showed 126 particularly elevated MVA-IgG titers after only one vaccine dose and their MVA IgG titers 127 remained stable over six months post vaccination. These results overall demonstrate that 128 COH04S1-vaccinated subjects develop potent orthopoxviral-specific IgG antibody responses.

129 Orthopoxviral-specific neutralizing antibodies induced in COH04S1-vaccinated subjects

130 MVA-specific neutralizing antibody (NAb) responses were measured on epithelial cells using a 131 high-throughput microneutralization assay. Similar to the observed MVA IgG responses in DL1-132 DL3 subjects, COH04S1-vaccinated subjects in all vaccine cohorts showed a strong increase in 133 MVA-specific NAb titers, consistent with potent vaccine-induced orthopoxviral-specific immunity 134 (Figure 2). Following prime vaccination, only a minor proportion of the DL1 subjects showed 135 elevated MVA-specific NAb titers, whereas all DL2 and DL3 subjects showed an increase in 136 MVA-specific NAb titers, confirming a dose-dependent vaccine effect after one dose (Figure 2A-137 B). While the DL1 cohorts showed a seroconversion rate of 0-60% after the first vaccination, DL2 and DL3 cohorts showed 100% seroconversion for MVA-specific NAb after the first dose 138 139 (Figure 2C). All subjects of the different vaccine cohorts developed robust MVA-specific NAb 140 titers at one month after the booster dose with NT50 titers ranging from 73 to >2,560 and a 141 median NT50 of 303, resulting in 100% seroconversion in all vaccine cohorts. DL2 and DL3

142 subjects tended to have slightly higher NAb titers than DL1 vaccinated volunteers. Similar to the 143 MVA IgG titers, MVA-specific NAb titers declined in all vaccine cohorts over five-months post-144 second vaccination, but they remained above baseline in most subjects, resulting in a median 145 NT50 titer of 65 and comparable titers across vaccine groups. Only two volunteers in the DL2 146 and DL3 vaccine cohorts had undetectable MVA-specific NAb titers. Interestingly, the same two 147 subjects with high baseline MVA binding IgG titers had pre-vaccination NAb titers approaching 148 the NT50 detection limit of 20, suggesting pre-existing orthopoxvirus-specific NAb responses in 149 these vaccinees (Figure S2). Placebo-vaccinated volunteers had consistently undetectable 150 MVA-specific NAb throughout the observation period (Figure 2). These results demonstrate that 151 subjects vaccinated with COH04S1 at different dose levels develop robust and durable 152 orthopoxvirus-specific NAb responses.

153 Orthopoxviral-specific cellular immunity induced in COH04S1-vaccinated subjects

154 Orthopoxvirus-specific T cells were evaluated after the second dose by assessing co-155 expression of IFNy with CD107a or CD69 activation markers on MVA-stimulated T cells using 156 flow cytometry (Figures S3-S4). CD107a marks cells capable of cytotoxic effector functions 157 while CD69 is an early T cell activation marker that is transiently upregulated by activated T 158 cells. Low levels of activated CD8⁺ and CD4⁺ T cells secreting IFNy upon MVA stimulation were 159 measured at baseline (Figures 3A and S5). COH04S1 vaccinees showed a significant increase 160 in CD107⁺ and CD69⁺ IFNγ-secreting CD8⁺ and CD4⁺ T cells at one month after the second 161 dose and they maintained significantly elevated levels of activated T cells over five months post-162 boost (Figures 3A and S5). Similar levels of MVA-specific T cells were observed independently 163 of dose level (Figure S5). In contrast, placebo subjects showed no or only low percentage of 164 MVA-specific T cells (Figure S5).

Phenotypic analysis of activated MVA-specific T cell subsets revealed that both CD8⁺ and CD4⁺ T cell populations in COH04S1 vaccinees were mostly comprised of T effector memory (T_{EM})

167 cells (Figure 3B). Terminally differentiated T_{EM} cells (T_{EMRA}) comprised about 20% of the CD8⁺ T cell population and were significantly higher than T_{EMRA} cells in the CD4⁺ population. Low 168 169 percentages of naïve and central memory (T_{CM}) T cells were measured in both CD8⁺ and CD4⁺ 170 T cell populations. Comparable percentages of activated naïve/T_{CM}/T_{EM}/T_{EMRA} T cells were 171 measured across the different DL vaccine cohorts (Figure S6A-B). Finally, a similar phenotype 172 distribution with predominance of T_{EM/EMRA} over T_{CM} was observed in the CD8⁺ and CD4⁺ T cell 173 populations at one and five months post booster vaccination (Figure S6C-D). These results 174 demonstrate that at all tested dose levels vaccination with COH04S1 induces robust and 175 durable orthopoxvirus-specific cellular responses with a predominant effector memory 176 phenotype.

177 Discussion

In this report, we demonstrate that multiantigen sMVA-based SARS-CoV-2 vaccine COH04S1 178 179 induces robust orthopoxvirus-specific immunity in a sub-group of healthy adults vaccinated 180 twice at different dose levels during a Phase I clinical trial aimed at testing safety and immunogenicity of COH04S1 as a COVID-19 vaccine¹⁸. Our findings show that COH04S1-181 182 vaccinated volunteers at all tested dose levels develop robust MVA-specific humoral and 183 cellular responses that remain detectable for up to six months post vaccination, suggesting that 184 COH04S1 represents a unique and clinically tested vaccine candidate to confer SARS-CoV-2 185 and orthopoxvirus immunity to simultaneously control the COVID-19 pandemic and the current 186 global monkeypox outbreak.

187 MVA-specific binding and neutralizing antibodies developed in all volunteers after two vaccine 188 doses resulting in 100% seroconversion. Consistent with a dose-escalation trial using a wildtype MVA²⁰ (ACAM3000), we found that post-prime antibody titers were affected by the vaccine 189 190 dose, with lower post-prime antibody titers in DL1 than in DL2/DL3 vaccinated subjects. 191 However, following the second dose, COH04S1 was similarly immunogenic at all DL tested. 192 Increased timing between vaccinations with DL1 did not affect the peak antibody response; 193 however, it seemed to marginally increase the magnitude of the long-term response compared 194 to volunteers vaccinated in a shorter interval, although a larger number of volunteers would be 195 needed to bolster this conclusion. No differences across DL were observed in magnitude and 196 phenotype of MVA-specific activated T cells indicating that the lowest dose was sufficient to 197 induce robust and durable cellular responses. This result is concordant with maximal induction of SARS-CoV-2 S- and N-specific T cells by COH04S1 at all DL tested¹⁸. 198

As previously observed by others, early post-vaccine T cell response to orthopoxvirus antigens
 was largely comprised of CD8⁺ T cells^{21,22}. Interestingly, COH04S1 induced higher MVA-specific
 CD8⁺ than CD4⁺ T cells, which is opposite to the previously observed SARS-CoV-2 S- and N-

specific CD8⁺ and CD4⁺ T-cells induced by COH04S1¹⁸, indicating that different antigens can 202 203 preferentially activate different T cell subtypes even during concomitant antigen stimulation. While it has been shown that T_{EM} are the predominant CD8⁺ subtype and T_{CM} the predominant 204 CD4⁺ T cell subtypes in SARS-CoV-2 infected or vaccinated individuals^{18,23,24}, we found that 205 206 MVA-specific T_{EM} cells were the predominant subtype in both CD8⁺ and CD4⁺ T cell populations 207 of COH04S1 vaccinees. Interestingly, T_{EM} cells, but not T_{CM} cells, have been demonstrated to protect against peripheral infection with vaccinia virus²⁵, highlighting an important protective role 208 209 of T_{EM} cells in orthopoxviral infections. Comprehensive studies of long-term immunity to vaccinia 210 have shown that T_{EM} cells decay with time after antigen encounter while T_{CM} cells have a greater capacity to persist in vivo²⁶. Whether the phenotype observed at six months post-211 212 vaccination in COH04S1-vaccinated subjects is maintained long-term or whether T_{CM} cells may 213 overtake T_{EM} cells as the main MVA-specific T cell subpopulation can only be clarified in long-214 term studies.

215 Smallpox and vaccinia immunity have been shown to be stable for decades after infection or vaccination and to decline only slowly over time^{27,28}. Of the two volunteers born before 1972, the 216 217 year of the end of the smallpox vaccination campaign, only one had an indication of low levels 218 pre-existing poxviral immunity. However, both volunteers responded to two COH04S1 doses 219 with higher-than-average long-lasting humoral responses, suggesting that vaccination with 220 COH04S1 successfully recalled low-to-undetectable vaccinia immunity acquired 50 years or 221 more before, which resulted in more robust and durable responses than in naïve subjects. 222 Interestingly, one DL3 subject born in 1986, and therefore not subjected to smallpox vaccination 223 during childhood, showed low-level poxviral pre-existing humoral immunity at baseline. The 224 same subject had a drastic increase in MVA-specific humoral response post-prime vaccination, 225 and binding and NAb at five months post-boost were exceptionally high. It is plausible that this 226 subject was recently inoculated with vaccinia due to work exposure risk and that a combination

of high COH04S1 dose with short time since smallpox vaccination contributed to the elevated MVA-specific responses. Importantly, this subject and the two volunteers born before 1972 developed robust SARS-CoV-2 S- and N-specific humoral and cellular responses¹⁸, suggesting that vector-specific pre-existing immunity did not prevent induction of robust immunity to the SARS-CoV-2 antigens of COH04S1.

232 Definition of correlates of protection against smallpox and monkeypox is complicated by the 233 contrasting findings emerged in the past decades. Orthopoxvirus-specific NAb but not CD8⁺ T 234 cells correlated with an attenuated Dryvax skin lesion or "take" at the inoculation site in one study²⁹, and NAb were necessary and sufficient to protect monkeys against monkeypox in 235 another study³⁰. On the other hand, a study in mice demonstrated an important protective role of 236 T cell immunity in the absence of an antibody response³¹, and patients with defects in their T 237 238 cell responses are those at risk to develop severe progressive vaccinia disease when 239 vaccinated³². Consequently, it seems likely that a complex interplay of immunological factors 240 contributes to the establishment of immunity to orthopoxviruses and these immunological 241 correlates may vary based on species and viral strain. Therefore, it is encouraging that 242 COH04S1-vaccination induced a comprehensive MVA-specific immunological response in 243 vaccinated volunteers.

Intramuscular doses of both ACAM3000 (1x10⁷ pfu) and Jynneos (1x10⁸ pfu) have been shown 244 245 to result in a significantly attenuated response to a Dryvax "take" in human challenge studies^{9,29,33} Considering that COH04S1 induced comparable humoral and cellular responses 246 247 post-boost at all dose levels tested, it is possible that COH04S1 would confer similar protection 248 to wild-type MVA vaccines against challenge starting from the lowest dose tested. However, non-inferiority clinical studies with immunological endpoints⁹ and challenge studies in non-249 250 human primates^{34,35} will be necessary to determine protective efficacy of COH04S1 against 251 smallpox and monkeypox.

252 Major limitation of the study is the small number of subjects included in the study. Nonetheless, 253 achievement of seroconversion and cellular responses in all subjects post-boost independent of 254 vaccine dose indicates that vaccination with COH04S1 induces robust MVA-specific immunity. 255 Because of biosafety limitations, we have not used vaccinia or monkeypox viruses for assessment of vaccine immunogenicity. However, magnitude of MVA- and vaccinia-specific 256 257 humoral immunity have been shown to be equivalent and vaccinia and monkeypox NAb targets 258 to be >94% conserved, indicating high degree of antibody cross-recognition between orthopoxviruses^{20,29,36}. Additionally, a comparison of binding and NAb titers induced by 259 260 COH04S1 with titers measured in the WHO "International Standard for Anti-Smallpox Serum" 63/024³⁷ was not possible since the product is currently not available in the NIBSC repository. 261 262 Finally, to measure NAb, we utilized a high throughput neutralization assay based on the use of 263 purified MVA intracellular mature virions, which are the main viral form liberated by cell lysis. We 264 have not evaluated vaccine-mediated neutralization of extracellular enveloped virions although this viral form is believed to be responsible for vaccinia virus inter-host dissemination³⁸. 265

266 Following the recent monkeypox outbreak numerous countries have rushed ordering Jynneos for their nationals in need for a total of more than 3 million doses³⁹. Additionally, the eventuality 267 268 of a mass monkeypox vaccination campaign in endemic African countries raises the issue of 269 vaccine supply shortage and equitable distribution. Consequently, there is an urgency to 270 stockpiles around the world with safe and effective third generation replenish 271 smallpox/monkeypox vaccines. The finding that COH04S1 induces robust and durable 272 orthopoxviral-specific immunity represent the fundamental preliminary result for allowing 273 COH04S1 and other sMVA-based vaccines to be tested in non-inferiority clinical trials as 274 vaccines against smallpox/monkeypox.

275 Methods

276 Human subjects

277 COH04S1 is a dual-antigen COVID-19 vaccine candidate based on a synthetic MVA 278 platform^{15,16,18}. COH04S1 immunogenicity was investigated at City of Hope (COH) as part of a 279 clinical protocol (IRB#20447) approved by an external Institutional Review Board (Advarra IRB). 280 This open-label and randomized, placebo controlled, phase 1 clinical study is registered 281 (NCT04639466). Among others, exclusion criteria included age<18 or >55, previous SARS-282 CoV-2 infection, BMI<18 or >35, underlying health conditions, and poxvirus vaccination within a 283 six-months period. All subjects gave informed consent at enrollment. Out of the 51 subjects who 284 received one or two doses of COH04S1, 5 subjects were selected from each dose group, for a 285 total of 20 subjects, based on 2 doses regimen and availability of frozen PBMCs samples. Subjects received two doses of COH04S1 at days 0 and 28. Five subjects were vaccinated with 286 dose level (DL) 1 ($1x10^7$ pfu), five with DL2 ($1x10^8$ pfu), and five with DL3 ($2.5x10^8$ pfu). 287 288 Additional five subjects received DL1 at day 0, placebo at day 28, and another DL1 at day 56. Four volunteers who received placebo at days 0 and 28 were included in the study. Two 289 290 subjects -one in DL1/DL1 group and one in DL2/DL2 group- were born before 1972 and therefore may have had been previously vaccinated against smallpox. Study population is 291 292 described on Table S1.

293 MVA IgG Endpoint ELISA

MVA-specific binding antibodies were evaluated by ELISA. ELISA plates (3361, Corning) were coated overnight at 4°C with 1□µg/mL of MVA expressing Venus fluorescent marker (MVA-Venus)¹³ in PBS pH 7.4. Plates were washed 5X with wash buffer (0.1% Tween-20/PBS), then blocked with 250 µl/well of assay buffer (0.5% casein/154mM NaCl/10mM Tris-HCl/0.1% Tween-20 [pH 7.6]/8% Normal goat serum) for 2 hours 37°C. After washing, 3-fold diluted heat-

299 inactivated serum in blocking buffer was added to the plates starting from a dilution of 1:150. 300 Plates were wrapped in foil and incubated 2 hours at 37°C. Plates were washed and 1:3,000 301 dilution of anti-human IgG HRP secondary antibody (BioRad 204005) in assay buffer was added 302 for 1 hour at room temperature. Plates were washed and developed with 1 Step TMB-Ultra 303 (Thermo Fisher 34029). After 2-4 minutes the reaction was stopped with 1M H_2SO_4 and 450nm 304 absorbance was immediately quantified on FilterMax F3 (Molecular Devices). Endpoint titers 305 were calculated as the highest dilution to have an absorbance >0.100 nm. Seroconversion was 306 defined a three or more times increase in baseline titer.

307 MVA neutralization assay

ARPE-19 cells were seeded in 96-well plates $(1.5 \square \times \square 10^4 \text{ cells/well})$. The following day, 2-fold 308 309 serial dilutions of serum starting from 1:10 were incubated for 2 h with MVA-Venus (multiplicity 310 of infection [MOI]=2). The serum-virus mixture was added to the cells in duplicate wells and 311 incubated for 24 h. After the 24 h incubation period, the cells were imaged using Leica DMi8 312 inverted microscope. Pictures from each well were processed using Image-Pro Premier (v9.2; 313 Media Cybernetics) and fluorescent cells corresponding to infection events were counted. The 314 neutralization titer for each dilution was calculated as follows: NT = = [1-(fluorescent cells with315 immune sera/fluorescent cells without immune sera)] x 100. The titers that gave 50% 316 neutralization (NT50) were calculated by determining the linear slope of the graph plotting NT 317 versus serum dilution by using the next higher and lower NT using Office Excel (v2019). Seroconversion was defined as an increase of two or more times the baseline titer⁹. 318

319 Quantification of vaccine-induced MVA specific T cells

Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using Ficoll and counted using Luna-FL cell counter (Logos Biosystems). Frozen PBMCs were thawed, counted and 1X10⁶ PBMCs were stimulated with MVA-Venus (MOI=1) for 24 hours in a total volume of

323 200 µl of RPMI media with 5% of human serum in a 96 wells plate. Unstimulated cells and PHA (20 µg/ml) were used as negative and positive controls, respectively. Anti-CD107a-APC, Golgi 324 325 Plug (Brefeldin A) and Golgi Stop (Monesin) were added 4 hours before staining. Cells were 326 washed with PBS and stained 15 min at room temperature with Live and dead near IR, anti-327 CD3-FITC, anti-CD4-BV421, anti-CD8-BV605, anti-CD69-PE, anti-CCR7-PE/Dazzle 594 and 328 anti-CD45-PerCP. After washing, cells were permeabilized with Fix/Perm (BD) for 20 minutes at 329 4°C. Cells were washed with Perm/Wash (BD) and intracellular stained with anti-IFNy-PECy7 330 for 30 minutes at 4°C, washed and resuspend in FACS buffer until acquisition. Cells were 331 acquired in Attune NxT cytometer (Thermofisher) and data was analyzed with Flow Jo X 332 software following the gating strategy described in Figure S3. Only one out of five DL3 333 volunteers had available PBMCs samples for the analysis.

334 Statistical analysis

335 Statistical analysis was performed using GraphPad Prism 8.3.0. Differences in humoral 336 responses across groups were compared using Kruskal-Wallis test followed by Dunn's multiple 337 comparison test. T cell percentages at different time-points were compared using two-tailed 338 Wilcoxon rank test. Differences in T cell subsets were evaluated using 2-way ANOVA followed 339 by Sidak's multiple comparison test.

340 Contributors

- 341 Study conceptualization: FC, FW, DJD. Study design: FC, FW. Immunological analysis: FC,
- 342 SOF, ML. Manuscript writing: FC, FW, DJD. Clinical PI: JAZ. All authors contributed to and
- 343 approved the final version of this manuscript.

345 **Declaration of interests**

346 While unknown whether publication of this report will aid in receiving grants and contracts, it is 347 possible that this publication will be of benefit to City of Hope (COH). COH had no role in the 348 conceptualization, design, data collection, analysis, decision to publish, or preparation of the 349 manuscript. DJD and FW are co-inventors on a patent application covering the design and 350 construction of the synthetic MVA platform (PCT/US2021/016247). DJD, FW, and FC are co-351 inventors on a patent application covering the development of a COVID-19 vaccine 352 (PCT/US2021/032821). DJD is a consultant for GeoVax. All other authors declare no competing 353 interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 under the 354 name of GEO-CM04S1.

355

357 Data sharing

- 358 We support data sharing of the individual de-identified participant data that underlie the results
- 359 reported in this article. Study protocols can be shared upon request by the corresponding
- author.

362 Acknowledgements

The Authors would like to thank all the participants who volunteered in the study and all the investigators and study site personnel who assisted in the clinical trial completion. Funding was provided by the Carol Moss Foundation, donors Julie and Roger Baskes, Judd Malkin, Michael Sweig, and the City of Hope Integrated Drug Development Venture program. We acknowledge and thank Christoph Pittius and Yuriy Shostak (Research Business Development, City of Hope) for excellent project management. We thank Christina Ulloa (Department of Hematology & HCT, City of Hope) for excellent support of investigators and meeting coordination.

371 References

- Kozlov, M. Monkeypox vaccination begins can the global outbreaks be contained?
 Nature, doi:10.1038/d41586-022-01587-1 (2022).
- 374 2 Fenner, F. The global eradication of smallpox. *Med J Aust* 1, 455-455,
 375 doi:10.5694/j.1326-5377.1980.tb135034.x (1980).
- Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox
 outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* 13, e0007791,
 doi:10.1371/journal.pntd.0007791 (2019).
- 379 4 Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after
 380 smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl*381 *Acad Sci U S A* **107**, 16262-16267, doi:10.1073/pnas.1005769107 (2010).
- 382
 5
 Durski, K. N. *et al.* Emergence of Monkeypox West and Central Africa, 1970-2017.

 383
 MMWR Morb Mortal Wkly Rep **67**, 306-310, doi:10.15585/mmwr.mm6710a5 (2018).
- 384 6 Jacobs, B. L. *et al.* Vaccinia virus vaccines: past, present and future. *Antiviral Res* **84**, 1-385 13, doi:10.1016/j.antiviral.2009.06.006 (2009).
- Volz, A. & Sutter, G. Modified Vaccinia Virus Ankara: History, Value in Basic Research,
 and Current Perspectives for Vaccine Development. *Adv Virus Res* 97, 187-243,
 doi:10.1016/bs.aivir.2016.07.001 (2017).
- Verheust, C., Goossens, M., Pauwels, K. & Breyer, D. Biosafety aspects of modified
 vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. *Vaccine* **30**, 2623-2632, doi:10.1016/j.vaccine.2012.02.016 (2012).
- Pittman, P. R. *et al.* Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. *N Engl J Med* 381, 1897-1908, doi:10.1056/NEJMoa1817307 (2019).
- Earl, P. L. *et al.* Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. *Proc Natl Acad Sci U S A* **105**, 10889-10894, doi:10.1073/pnas.0804985105 (2008).
- Chiuppesi, F. *et al.* Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To
 Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus
 in Mice. J Virol 92, doi:10.1128/JVI.01012-18 (2018).
- La Rosa, C. *et al.* MVA vaccine encoding CMV antigens safely induces durable
 expansion of CMV-specific T cells in healthy adults. *Blood* 129, 114-125,
 doi:10.1182/blood-2016-07-729756 (2017).
- 40313Wussow, F. et al. Human cytomegalovirus vaccine based on the envelope gH/gL404pentamer complex. PLoS Pathog 10, e1004524, doi:10.1371/journal.ppat.1004524405(2014).
- 406 14 Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.
 408 *Virology* 244, 365-396, doi:10.1006/viro.1998.9123 (1998).
- Chiuppesi, F. *et al.* Development of a multi-antigenic SARS-CoV-2 vaccine candidate
 using a synthetic poxvirus platform. *Nat Commun* **11**, 6121, doi:10.1038/s41467-02019819-1 (2020).
- Chiuppesi, F. *et al.* Synthetic multiantigen MVA vaccine COH04S1 protects against
 SARS-CoV-2 in Syrian hamsters and non-human primates. *NPJ Vaccines* 7, 7,
 doi:10.1038/s41541-022-00436-6 (2022).
- 415 17 Wussow, F. *et al.* COH04S1 and Beta Sequence Modified Vaccine Protect Hamsters 416 From SARS-CoV-2 Variants. *iScience*, 104457, doi:10.1016/j.isci.2022.104457 (2022).
- 417 18 Chiuppesi, F. *et al.* Safety and immunogenicity of a synthetic multiantigen modified 418 vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and 419 randomised, phase 1 trial. *Lancet Microbe*, doi:10.1016/S2666-5247(22)00027-1 (2022).

- Chiuppesi, F. *et al.* Vaccine-induced spike- and nucleocapsid-specific cellular responses
 maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. *iScience*,
 104745, doi:10.1016/j.isci.2022.104745 (2022).
- Wilck, M. B. *et al.* Safety and immunogenicity of modified vaccinia Ankara (ACAM3000):
 effect of dose and route of administration. *J Infect Dis* 201, 1361-1370,
 doi:10.1086/651561 (2010).
- 42621Miller, J. D. *et al.* Human effector and memory CD8+ T cell responses to smallpox and
yellow fever vaccines. *Immunity* 28, 710-722, doi:10.1016/j.immuni.2008.02.020 (2008).
- Amara, R. R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. Long-lived poxvirus immunity,
 robust CD4 help, and better persistence of CD4 than CD8 T cells. *J Virol* 78, 3811-3816,
 doi:10.1128/jvi.78.8.3811-3816.2004 (2004).
- 431 23 Gao, Y. *et al.* Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron 432 variant. *Nat Med*, doi:10.1038/s41591-022-01700-x (2022).
- 433 24 Neidleman, J. *et al.* SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper
 434 Function, Lack of Terminal Differentiation, and High Proliferation Potential. *Cell Rep Med*435 1, 100081, doi:10.1016/j.xcrm.2020.100081
- 436 S2666-3791(20)30102-6 (2020).
- Bachmann, M. F., Wolint, P., Schwarz, K., Jager, P. & Oxenius, A. Functional properties
 and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor
 alpha and CD62L. *J Immunol* **175**, 4686-4696, doi:10.4049/jimmunol.175.7.4686 (2005).
- 440 26 Puissant, B. & Combadiere, B. Keeping the memory of smallpox virus. *Cell Mol Life Sci* **63**, 2249-2259, doi:10.1007/s00018-006-6313-2 (2006).
- 442 27 Hanna, W. & Baxby, D. Studies in smallpox and vaccination. 1913. *Rev Med Virol* 12, 201-209, doi:10.1002/rmv.361 (2002).
- 44428Crotty, S. et al. Cutting edge: long-term B cell memory in humans after smallpox445vaccination. J Immunol 171, 4969-4973, doi:10.4049/jimmunol.171.10.4969 (2003).
- Seaman, M. S. *et al.* Effect of vaccination with modified vaccinia Ankara (ACAM3000) on
 subsequent challenge with Dryvax. *J Infect Dis* 201, 1353-1360, doi:10.1086/651560
 (2010).
- Edghill-Smith, Y. *et al.* Smallpox vaccine-induced antibodies are necessary and
 sufficient for protection against monkeypox virus. *Nat Med* **11**, 740-747,
 doi:10.1038/nm1261 (2005).
- 452 31 Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. Highly attenuated smallpox vaccine 453 protects mice with and without immune deficiencies against pathogenic vaccinia virus 454 challenge. *Proc Natl Acad Sci U S A* **101**, 4590-4595, doi:10.1073/pnas.0401165101 455 (2004).
- 456 32 Bray, M. & Wright, M. E. Progressive vaccinia. *Clin Infect Dis* **36**, 766-774, doi:10.1086/374244 (2003).
- 458 33 Frey, S. E. *et al.* Clinical and immunologic responses to multiple doses of IMVAMUNE
 459 (Modified Vaccinia Ankara) followed by Dryvax challenge. *Vaccine* 25, 8562-8573, doi:10.1016/j.vaccine.2007.10.017 (2007).
- 461 34 Earl, P. L. *et al.* Immunogenicity of a highly attenuated MVA smallpox vaccine and 462 protection against monkeypox. *Nature* **428**, 182-185, doi:10.1038/nature02331 (2004).
- 463 35 Stittelaar, K. J. *et al.* Modified vaccinia virus Ankara protects macaques against
 464 respiratory challenge with monkeypox virus. *J Virol* **79**, 7845-7851,
 465 doi:10.1128/JVI.79.12.7845-7851.2005 (2005).
- Ahmed, S. F., Sohail, M. S., Quadeer, A. A. & mcKay, M. R. Vaccinia virus vaccination is
 expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. *BioRxiv*,
 doi:10.1101/2022.06.23.497143 (2022).

- 469 37 Anderson, S. G. & Skegg, J. The international standard for anti-smallpox serum. *Bull*470 *World Health Organ* 42, 515-523 (1970).
- 38 Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular
 472 enveloped vaccinia virus. *J Gen Virol* 83, 2915-2931, doi:10.1099/0022-1317-83-12473 2915 (2002).
- 474 39
 475 39
 475 476
 476 HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox doi:<u>https://www.hhs.gov/about/news/2022/07/01/hhs-orders-2-point-5-</u>
 476 million-more-doses-jynneos-vaccine-for-monkeypox-preparedness.html (2022).
- 477





Figure 1. MVA-specific binding IgG in COH04S1 vaccinees. A-B. Binding antibodies. MVA-480 481 specific IgG titers were measured by ELISA in subjects before vaccination, post-prime 482 vaccination, and at one and five months post-booster vaccination with COH04S1 at dose-level 483 (DL) 1 (DL1/DL1 and DL1/placebo/DL1), DL2 (DL2/DL2), and DL3 (DL3/DL3). Subjects who 484 received placebo vaccination were used as negative controls. Black triangles in B indicate time 485 point of vaccination in DL1/DL1, DL2/DL2, and DL3/DL3 groups. Purple triangles indicate time 486 of DL1 vaccinations in DL1/placebo/DL1 group. Red asterisks indicate subjects in DL1/DL1 and 487 DL2/DL2 cohorts that were born before 1972. Black asterisk indicates the DL3 subject born in 1986 with suspected orthopoxvirus pre-existing immunity. Kruskal-Wallis test followed by 488 489 Dunn's multiple comparison test was used in A (*=p<0.05, **=p<0.01). **C.** Seroconversion rate. 490 Shown is the percentage of seroconverted volunteers with MVA-specific NAb titers ≥3-fold 491 above baseline at different time points post-vaccination with COH04S1.



492

493 Figure 2. MVA-specific neutralizing response in COH04S1 vaccinees. A-B. Neutralizing 494 antibodies (NAb). MVA-specific NAb titers preventing 50% infection (NT50) were measured with 495 a high-throughput neutralization assay. NAb were measured before vaccination, post-prime 496 vaccination, and at one and five months post-booster vaccinations with COH04S1 at dose-level 497 (DL) 1 (DL1/DL1 and DL1/placebo/DL1), DL2 (DL2/DL2), and DL3 (DL3/DL3). Subjects who 498 received placebo vaccination were used as negative controls. Black triangles in B indicate time 499 of vaccinations in DL1/DL1, DL2/DL2, and DL3/DL3 groups. Purple triangles indicate time of 500 DL1 vaccinations in DL1/placebo/DL1 group. Red asterisks indicate subjects in DL1/DL1 and 501 DL2/DL2 cohorts that were born <1972. Black asterisk indicates the DL3 subject born in 1986 502 with suspected orthopoxvirus pre-existing immunity. Kruskal-Wallis test followed by Dunn's 503 multiple comparison test was used in A (*=p<0.05, **=p<0.01). **C.** Seroconversion rate. Shown 504 is the percentage of seroconverted volunteers with MVA-specific NAb titers above baseline at 505 different time points post-vaccination with COH04S1.





Figure 3. MVA-specific T cell response in COH04S1 vaccinees. A. $IFN\gamma^+/CD107^+$ and IFN $\gamma^+/CD69^+$ CD8⁺ and CD4⁺ T cell percentages were measured by cytofluorimetry in PBMC samples at baseline, and at one and five months post-booster vaccinations with COH04S1 at all dose levels. Activated T cell percentages at one and five months (mo) post-boost were compared to baseline levels using two-tailed Wilcoxon signed-rank test. **B.** Phenotypic analysis of antigen-specific T lymphocytes was performed using samples collected one month post-

513 second dose. Shown are percentages of naïve, central memory (T_{CM}), effector memory (T_{EM}), 514 and terminally differentiated effector memory (T_{EMRA}) T cells measured in IFN γ^+ /CD69⁺ CD8⁺ 515 and CD4⁺ T cell populations. 2-way ANOVA followed by Sidak's multiple comparison test was 516 used to compare groups. P values are indicated in the figure. In A-B box plots extend from the 517 25th to the 75th percentiles, median values are shown as a line, whiskers extend from minimum 518 to maximum values.